Arbutus Biopharma Corporation
ABUS
$5.15
-$0.03-0.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -90.56% | 10,054.54% | -33.23% | -60.49% | 522.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.56% | 10,054.54% | -33.23% | -60.49% | 522.19% |
| Cost of Revenue | -47.29% | -54.01% | -43.18% | -59.52% | -64.65% |
| Gross Profit | -135.95% | 2,532.33% | 45.34% | 59.42% | 137.91% |
| SG&A Expenses | 16.20% | 0.98% | -21.71% | -32.91% | -55.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.35% | -32.33% | -35.70% | -53.10% | -61.79% |
| Operating Income | -400.63% | 1,398.20% | 36.02% | 52.53% | 108.95% |
| Income Before Tax | -303.84% | 791.90% | 70.03% | 60.73% | 112.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -303.84% | 791.90% | 70.03% | 60.73% | 112.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -303.84% | 791.90% | 70.03% | 60.73% | 112.74% |
| EBIT | -400.63% | 1,398.20% | 36.02% | 52.53% | 108.95% |
| EBITDA | -398.34% | 1,432.03% | 34.28% | 51.67% | 109.15% |
| EPS Basic | -296.97% | 781.03% | 70.50% | 61.27% | 112.54% |
| Normalized Basic EPS | -262.50% | 1,512.37% | 36.60% | 53.93% | 114.75% |
| EPS Diluted | -400.00% | 769.23% | 70.50% | 61.27% | 109.09% |
| Normalized Diluted EPS | -262.50% | 1,502.06% | 36.60% | 53.93% | 114.75% |
| Average Basic Shares Outstanding | 3.09% | 1.61% | 1.40% | 1.47% | 1.87% |
| Average Diluted Shares Outstanding | 2.64% | 2.36% | 1.40% | 1.47% | 2.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |